Michael E. Kopach
Research Subjects
Michael E. Kopach has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Albert Isidro-Llobet
GSK, Gunnels Wood Road, Stevenage, UK
3 shared publications Ankur Jalan
Eli Lilly and Company
3 shared publicationsEmily Murzinski Valco
Lilly Research Laboratories, Eli Lilly and Company
3 shared publications- Jennifer L. Stockdill
Department of Chemistry
3 shared publications Mark R. Berglund
Lilly Research Laboratories, Eli Lilly and Company
3 shared publications- Subha Mukherjee
Chemical Process Development, Bristol Myers Squibb, New Brunswick, New Jersey 08903, United States
3 shared publications
Latest Publications
- 22 October 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (11) , 3012-3032
Synthesis of a Crystalline Acylated Lysine Building Block for Retatrutide Manufacture
Retatrutide contains a structurally complex lipidated side chain that presents significant challenges for efficient large-scale synthesis and isolation. We report the development of a novel and highly efficient commercial synthetic route to the lipidated side chain, designed to enable robust and sustainable manufacture at multimetric-ton scale. A central innovation of this process is the successful crystallization of an acylated lysine building block─a rare outcome for lipidated amino-acid-derived materials─which enables a chromatography-free isolation strategy and provides consistent solid-state quality. The optimized route leverages flow chemistry for key transformations in combination with crystallization-based purification, resulting in improved convergence, throughput, and operational robustness. Process mass intensity (PMI) analysis indicates a total raw material usage of 152 kg per kg of acylated lysine, with solvent consumption dominated by water and acetonitrile. Compared to a solid-phase synthetic route to the same intermediate, the liquid-phase process reduces total PMI by more than 65% and eliminates piperidine from the synthesis, representing a substantive improvement in manufacturing efficiency. Solvent usage in the final transformation was evaluated with an emphasis on process flexibility; preliminary studies demonstrate that DMSO provided comparable solubility and impurity profiles under manufacturing conditions, offering a potential path to complete elimination of DMF from the synthesis and further reduction of PMI. The process has been successfully incorporated into the retatrutide validation supply chain and is expected to support multimetric-ton-scale manufacture. The route consistently delivers ≥99% purity crystalline acylated lysine, which serves as a critical registered starting material for the commercial manufacture of retatrutide.
- 22 October 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (11) , 3012-3032
Synthesis of a Crystalline Acylated Lysine Building Block for Retatrutide Manufacture
Retatrutide contains a structurally complex lipidated side chain that presents significant challenges for efficient large-scale synthesis and isolation. We report the development of a novel and highly efficient commercial synthetic route to the lipidated side chain, designed to enable robust and sustainable manufacture at multimetric-ton scale. A central innovation of this process is the successful crystallization of an acylated lysine building block─a rare outcome for lipidated amino-acid-derived materials─which enables a chromatography-free isolation strategy and provides consistent solid-state quality. The optimized route leverages flow chemistry for key transformations in combination with crystallization-based purification, resulting in improved convergence, throughput, and operational robustness. Process mass intensity (PMI) analysis indicates a total raw material usage of 152 kg per kg of acylated lysine, with solvent consumption dominated by water and acetonitrile. Compared to a solid-phase synthetic route to the same intermediate, the liquid-phase process reduces total PMI by more than 65% and eliminates piperidine from the synthesis, representing a substantive improvement in manufacturing efficiency. Solvent usage in the final transformation was evaluated with an emphasis on process flexibility; preliminary studies demonstrate that DMSO provided comparable solubility and impurity profiles under manufacturing conditions, offering a potential path to complete elimination of DMF from the synthesis and further reduction of PMI. The process has been successfully incorporated into the retatrutide validation supply chain and is expected to support multimetric-ton-scale manufacture. The route consistently delivers ≥99% purity crystalline acylated lysine, which serves as a critical registered starting material for the commercial manufacture of retatrutide.
- 8 September 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (37) , 16982-16996
A DMF-Free Large Scale Solid-Phase Synthesis of the Linear Precursor of Sunflower Trypsin Inhibitor-1 Guided by Sustainability Principles
Solid-phase peptide synthesis (SPPS) at commercial scale depends on three substances now subject to tightening regulatory pressure: dimethylformamide (DMF), classified as a reprotoxic substance of very high concern under EU REACH; dichloromethane (DCM), broadly prohibited for industrial use in the United States under the 2024 EPA TSCA rule; and piperidine, a DEA Schedule I precursor requiring licensed handling and disposal at manufacturing scale. We report a 50 mmol, DMF-free synthesis of the linear precursor of sunflower trypsin inhibitor-1 (SFTI-1) that simultaneously eliminates all three substances from a pharmaceutically relevant Fmoc/tBu SPPS process without compromising yield, purity, or stereochemical integrity. DCM-free resin loading and swelling were achieved using 1:1 EtOAc/ACN; coupling and Fmoc deprotection were conducted in 1:1 NBP/EtOAc throughout, with 2% DBU replacing 20% piperidine — reducing deprotection base consumption by 91%. Operating at 1.5 equivalents of amino acid and coupling reagents vs the conventional 3.0 equivalents delivered a 50% reduction in stoichiometric inputs. The principal synthetic challenge, arginine coupling, was addressed through high-throughput experimentation identifying 2:3 DMSO/1,3-dioxolane at 40 °C as a greener solvent system achieving 97% conversion. Head-to-head comparison against a conventional DMF benchmark confirmed equivalent potency-corrected peptide output, comparable crude purity, and no increase in epimerization across all nine chiral residues. Collectively, these improvements delivered an estimated 9% reduction in total process mass intensity (PMI) relative to the DMF process (847 vs 934 kg/kg crude peptide), with the dominant gains concentrated in deprotection base and reagent stoichiometry. Normalized per amino acid to enable comparison with reported industry benchmarks, both the conventional (66.7 kg/kg per amino acid) and green (60.5 kg/kg per amino acid) variants of this process already operate roughly an order of magnitude below the average PMI reported for commercial-scale SPPS in a recent multicompany benchmarking analysis (874.5 kg/kg per amino acid) (J. Org. Chem. 2024, 89, 4261−4282). These results provide a compliance-ready, industrially validated framework for commercial SPPS under current and forthcoming regulatory constraints.
- 8 September 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (37) , 16982-16996
A DMF-Free Large Scale Solid-Phase Synthesis of the Linear Precursor of Sunflower Trypsin Inhibitor-1 Guided by Sustainability Principles
Solid-phase peptide synthesis (SPPS) at commercial scale depends on three substances now subject to tightening regulatory pressure: dimethylformamide (DMF), classified as a reprotoxic substance of very high concern under EU REACH; dichloromethane (DCM), broadly prohibited for industrial use in the United States under the 2024 EPA TSCA rule; and piperidine, a DEA Schedule I precursor requiring licensed handling and disposal at manufacturing scale. We report a 50 mmol, DMF-free synthesis of the linear precursor of sunflower trypsin inhibitor-1 (SFTI-1) that simultaneously eliminates all three substances from a pharmaceutically relevant Fmoc/tBu SPPS process without compromising yield, purity, or stereochemical integrity. DCM-free resin loading and swelling were achieved using 1:1 EtOAc/ACN; coupling and Fmoc deprotection were conducted in 1:1 NBP/EtOAc throughout, with 2% DBU replacing 20% piperidine — reducing deprotection base consumption by 91%. Operating at 1.5 equivalents of amino acid and coupling reagents vs the conventional 3.0 equivalents delivered a 50% reduction in stoichiometric inputs. The principal synthetic challenge, arginine coupling, was addressed through high-throughput experimentation identifying 2:3 DMSO/1,3-dioxolane at 40 °C as a greener solvent system achieving 97% conversion. Head-to-head comparison against a conventional DMF benchmark confirmed equivalent potency-corrected peptide output, comparable crude purity, and no increase in epimerization across all nine chiral residues. Collectively, these improvements delivered an estimated 9% reduction in total process mass intensity (PMI) relative to the DMF process (847 vs 934 kg/kg crude peptide), with the dominant gains concentrated in deprotection base and reagent stoichiometry. Normalized per amino acid to enable comparison with reported industry benchmarks, both the conventional (66.7 kg/kg per amino acid) and green (60.5 kg/kg per amino acid) variants of this process already operate roughly an order of magnitude below the average PMI reported for commercial-scale SPPS in a recent multicompany benchmarking analysis (874.5 kg/kg per amino acid) (J. Org. Chem. 2024, 89, 4261−4282). These results provide a compliance-ready, industrially validated framework for commercial SPPS under current and forthcoming regulatory constraints.
- 14 August 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (34) , 15362-15373
Development of a Polar Tag Platform for Sustainable Tag-Assisted Liquid-Phase Peptide Synthesis (TA-LPPS)
Tag-assisted liquid-phase peptide synthesis (TA-LPPS) has emerged as a potential solution to synthetic bottlenecks associated with solid-phase peptide synthesis (SPPS) and long development times required for classical liquid-phase peptide synthesis (LPPS). Modern TA-LPPS utilizes hydrophobic alkyl chains attached to the peptide to assist extraction or precipitation after each synthetic step. Unfortunately, these highly nonpolar structures are also prone to self-aggregation and solubility challenges during synthesis. In contrast, the seminal report of TA-LPPS utilized tags derived from polar polydisperse PEG ∼20,000 Da chains, which demonstrated excellent peptide solubility in the polar organic solvents needed for peptide synthesis. Despite their enhanced solubility, polar tags have been overlooked due to the polydispersity of the PEG polymer, which severely complicates LC-MS analysis of tagged products. Herein, we report a monodisperse polar tag (ADO10), which is derived from 2-[2-(2-aminoethoxy)ethoxy]acetic acid (AEEA)—a commercial and low-cost starting material. ADO10 utilizes conventional Fmoc/t-Bu protecting groups and greatly simplifies LC-MS reaction monitoring. Rather than aqueous extraction or precipitation, ADO10 tags utilize a unique organic–organic liquid–liquid separation in green solvents—balancing phase separation speed and effective impurity removal. The established polar TA-LPPS platform is capable of gram-scale synthesis of multiple biologically active peptides including a fragment of semaglutide. Furthermore, we demonstrate that the enhanced solubility of polar tags can resolve challenges observed for SPPS of an aggregation-prone peptide Aβ(25–35).
- 14 August 2026
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 14 (34) , 15362-15373
Development of a Polar Tag Platform for Sustainable Tag-Assisted Liquid-Phase Peptide Synthesis (TA-LPPS)
Tag-assisted liquid-phase peptide synthesis (TA-LPPS) has emerged as a potential solution to synthetic bottlenecks associated with solid-phase peptide synthesis (SPPS) and long development times required for classical liquid-phase peptide synthesis (LPPS). Modern TA-LPPS utilizes hydrophobic alkyl chains attached to the peptide to assist extraction or precipitation after each synthetic step. Unfortunately, these highly nonpolar structures are also prone to self-aggregation and solubility challenges during synthesis. In contrast, the seminal report of TA-LPPS utilized tags derived from polar polydisperse PEG ∼20,000 Da chains, which demonstrated excellent peptide solubility in the polar organic solvents needed for peptide synthesis. Despite their enhanced solubility, polar tags have been overlooked due to the polydispersity of the PEG polymer, which severely complicates LC-MS analysis of tagged products. Herein, we report a monodisperse polar tag (ADO10), which is derived from 2-[2-(2-aminoethoxy)ethoxy]acetic acid (AEEA)—a commercial and low-cost starting material. ADO10 utilizes conventional Fmoc/t-Bu protecting groups and greatly simplifies LC-MS reaction monitoring. Rather than aqueous extraction or precipitation, ADO10 tags utilize a unique organic–organic liquid–liquid separation in green solvents—balancing phase separation speed and effective impurity removal. The established polar TA-LPPS platform is capable of gram-scale synthesis of multiple biologically active peptides including a fragment of semaglutide. Furthermore, we demonstrate that the enhanced solubility of polar tags can resolve challenges observed for SPPS of an aggregation-prone peptide Aβ(25–35).
- Top Cited PapersOpen Access
- 27 April 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (5) , 1071-1081
Perspectives on Sustainability in the Pharmaceutical Industry
- 27 April 2026
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 30 (5) , 1071-1081
Top Cited PapersOpen AccessPerspectives on Sustainability in the Pharmaceutical Industry
- 23 October 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (11) , 2896-2907
Advancing Peptide Synthesis: Liquid-Phase Assembly of Tirzepatide’s C-Terminus (30–39) via Crystalline Pentamer Building Blocks
- 23 October 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (11) , 2896-2907
Advancing Peptide Synthesis: Liquid-Phase Assembly of Tirzepatide’s C-Terminus (30–39) via Crystalline Pentamer Building Blocks
- Open Access
- 31 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
A Novel Hybrid SPPS/LPPS Strategy for the Synthesis of Tirzepatide via Native Chemical Ligation
The development of scalable, efficient manufacturing processes for high-volume, complex synthetic peptide and proteins remains a significant challenge, largely due to the limitations of traditional Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS).[1] To enable the commercial synthesis of Tirzepatide (TZP, 1), we designed an innovative four-fragment hybrid SPPS/LPPS strategy that integrates the strengths of both platforms.[2] This approach, coupled with flow chemistry for fragment condensation and nanofiltration for intermediate purification, represents a step-change in process efficiency for large-scale peptide production. Given the broader reliance on inefficient linear SPPS in the field, our work underscores the potential of hybrid synthesis strategies to transform peptide manufacturing. In parallel with commercial process development, we established an alternative two-fragment synthesis route using Native Chemical Ligation (NCL) followed by tandem desulfurization. This method enables the chemoselective coupling of two unprotected peptide fragments in aqueous media without epimerization, offering a powerful, orthogonal route to TZP. Together, these advances represent meaningful innovation in synthetic peptide process chemistry.
- 31 August 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Novel Hybrid SPPS/LPPS Strategy for the Synthesis of Tirzepatide via Native Chemical Ligation
The development of scalable, efficient manufacturing processes for high-volume, complex synthetic peptide and proteins remains a significant challenge, largely due to the limitations of traditional Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS).[1] To enable the commercial synthesis of Tirzepatide (TZP, 1), we designed an innovative four-fragment hybrid SPPS/LPPS strategy that integrates the strengths of both platforms.[2] This approach, coupled with flow chemistry for fragment condensation and nanofiltration for intermediate purification, represents a step-change in process efficiency for large-scale peptide production. Given the broader reliance on inefficient linear SPPS in the field, our work underscores the potential of hybrid synthesis strategies to transform peptide manufacturing. In parallel with commercial process development, we established an alternative two-fragment synthesis route using Native Chemical Ligation (NCL) followed by tandem desulfurization. This method enables the chemoselective coupling of two unprotected peptide fragments in aqueous media without epimerization, offering a powerful, orthogonal route to TZP. Together, these advances represent meaningful innovation in synthetic peptide process chemistry.
- Open Access
- 27 June 2025
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 13 (27) , 10268-10284
Environmental Sustainability Strategy of Active Pharmaceutical Ingredient Manufacturing: A Perspective from the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable
- 27 June 2025
- Published by American Chemical Society (ACS) in ACS Sustainable Chemistry & Engineering
- Vol. 13 (27) , 10268-10284
Open AccessEnvironmental Sustainability Strategy of Active Pharmaceutical Ingredient Manufacturing: A Perspective from the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable
- Top Cited PapersOpen Access
- 20 March 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (7) , 4261-4282
Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis. SPPS involves the use of excess solvents and reagents which negatively impact the environment, thus highlighting the need for newer technologies to reduce the environmental footprint. Herein, fourteen American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) member companies with peptide-based therapeutics in their portfolio have compiled Process Mass Intensity (PMI) metrics to help inform the sustainability efforts in peptide synthesis. This includes PMI assessment on 40 synthetic peptide processes at various development stages in pharma, classified according to the development phase. This is the most comprehensive assessment of synthetic peptide environmental metrics to date. The synthetic peptide manufacturing process was divided into stages (synthesis, purification, isolation) to determine their respective PMI. On average, solid-phase peptide synthesis (SPPS) (PMI ≈ 13,000) does not compare favorably with other modalities such as small molecules (PMI median 168-308) and biopharmaceuticals (PMI ≈ 8300). Thus, the high PMI for peptide synthesis warrants more environmentally friendly processes in peptide manufacturing.
- 20 March 2024
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 89 (7) , 4261-4282
Top Cited PapersOpen AccessProcess Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis. SPPS involves the use of excess solvents and reagents which negatively impact the environment, thus highlighting the need for newer technologies to reduce the environmental footprint. Herein, fourteen American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) member companies with peptide-based therapeutics in their portfolio have compiled Process Mass Intensity (PMI) metrics to help inform the sustainability efforts in peptide synthesis. This includes PMI assessment on 40 synthetic peptide processes at various development stages in pharma, classified according to the development phase. This is the most comprehensive assessment of synthetic peptide environmental metrics to date. The synthetic peptide manufacturing process was divided into stages (synthesis, purification, isolation) to determine their respective PMI. On average, solid-phase peptide synthesis (SPPS) (PMI ≈ 13,000) does not compare favorably with other modalities such as small molecules (PMI median 168-308) and biopharmaceuticals (PMI ≈ 8300). Thus, the high PMI for peptide synthesis warrants more environmentally friendly processes in peptide manufacturing.
- Open Access
- 4 October 2023
- Published by American Chemical Society (ACS) in ChemRxiv
A Serine Ligation Method Based on Mitsunobu Reaction and O-to-N Acyl Transfer
A ligation protocol has been developed in which a peptide containing an N-terminal serine is linked via its side-chain alcohol to the C-terminal carboxylate of a second peptide by Mitsunobu esterification. N-Deprotection of the serine and subsequent exposure to a weak amine base triggers O-to-N acyl transfer, delivering the desired ligation product. A unique aspect of this strategy is the use of the C-terminal carboxylate as a nucleophile rather than as an electrophile. As a result, the ligation occurs without evidence of epimerization. A broad scope of C-terminal nucleophiles is tolerated, including proline and hindered beta-branched residues.
- 4 October 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA Serine Ligation Method Based on Mitsunobu Reaction and O-to-N Acyl Transfer
A ligation protocol has been developed in which a peptide containing an N-terminal serine is linked via its side-chain alcohol to the C-terminal carboxylate of a second peptide by Mitsunobu esterification. N-Deprotection of the serine and subsequent exposure to a weak amine base triggers O-to-N acyl transfer, delivering the desired ligation product. A unique aspect of this strategy is the use of the C-terminal carboxylate as a nucleophile rather than as an electrophile. As a result, the ligation occurs without evidence of epimerization. A broad scope of C-terminal nucleophiles is tolerated, including proline and hindered beta-branched residues.
- Open Access
- 31 May 2023
- Published by Swiss Chemical Society in Chimia
- Vol. 77 (5) , 319
The History of Flow Chemistry at Eli Lilly and Company
Flow chemistry was initially used for speed to early phase material delivery in the development laboratories, scaling up chemical transformations that we would not or could not scale up batch for safety reasons. Some early examples included a Newman Kwart Rearrangement, Claisen rearrangement, hydroformylation, and thermal imidazole cyclization. Next, flow chemistry was used to enable safe scale up of hazardous chemistries to manufacturing plants. Examples included high pressure hydrogenation, aerobic oxidation, and Grignard formation reactions. More recently, flow chemistry was used in Small Volume Continuous (SVC) processes, where highly potent oncolytic molecules were produced by fully continuous processes at about 10 kg/day including reaction, extraction, distillation, and crystallization, using disposable equipment contained in fume hoods.
- 31 May 2023
- Published by Swiss Chemical Society in Chimia
- Vol. 77 (5) , 319
Open AccessThe History of Flow Chemistry at Eli Lilly and Company
Flow chemistry was initially used for speed to early phase material delivery in the development laboratories, scaling up chemical transformations that we would not or could not scale up batch for safety reasons. Some early examples included a Newman Kwart Rearrangement, Claisen rearrangement, hydroformylation, and thermal imidazole cyclization. Next, flow chemistry was used to enable safe scale up of hazardous chemistries to manufacturing plants. Examples included high pressure hydrogenation, aerobic oxidation, and Grignard formation reactions. More recently, flow chemistry was used in Small Volume Continuous (SVC) processes, where highly potent oncolytic molecules were produced by fully continuous processes at about 10 kg/day including reaction, extraction, distillation, and crystallization, using disposable equipment contained in fume hoods.